Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
take advantage of. This position participates in a retirement program (pension or optional retirement plan/ORP) that must be selected and is effective on your date of hire. Exempt regular staff receive a
-
. The referenced salary range reflects base pay, which is based on faculty rank and years in rank. This salary range does not include all components of the Department of Pathology faculty compensation program or pay
-
. The referenced salary range reflects base pay, which is based on faculty rank and years in rank. This salary range does not include all components of the Department of Pathology faculty compensation program or pay
-
or Associate Professor jointly appointed between the Institute for Genome Sciences (IGS), the Institute for Health Computing (IHC), and the Greenebaum Comprehensive Cancer Center (UMGCCC). Applicants
-
. The Division of General OB/GYN has a strong urban community based clinical program within the context of an academic environment. The candidate will be challenged to provide quality care in on- and off-campus
-
(UMSOP) Department of Practice, Sciences, and Health Outcomes Research (P-SHOR) has an opening for an Administrative Assistant II for the Peer Review Program for Psychiatric Medications. This program is
-
in rank. This salary range does not include all components of the Department of Pathology faculty compensation program or pay from participation in the Department of Pathology variable compensation
-
in rank. This salary range does not include all components of the Department of Pathology faculty compensation program or pay from participation in the Department of Pathology variable compensation
-
Clinical Research Specialist for the Hematologic Malignancies research program. This position will be patient-facing and responsible for implementing clinical research protocols on behalf of the faculty
-
). Following an extensive training program, the Bone Marrow Research Specialist will be assigned a portfolio of cutting-edge Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and other novel therapeutic trials